Activating mutations of KIT and platelet-derived growth factor receptor a (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression profile of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.
Activating mutations of KIT and platelet-derived growth factor receptor a (PDGFRA) are known to be alternative and mutually exclusive genetic events in the development of gastrointestinal stromal tumors (GISTs). We examined the effect of the mutations of these two genes on the gene expression profile of 22 GISTs using the oligonucleotide microarray. Mutations of KIT and PDGFRA were found in 17 cases and three cases, respectively. The remaining two cases had no detectable mutations in either gene. The mutation status of KIT and PDGFRA was directly related to the expression levels of activated KIT and PDGFRA, and was also related to the different expression levels of activated proteins that play key roles in the downstream of the receptor tyrosine kinase III family. To evaluate the impact of mutation status and the importance of the type of mutation in gene expression and clinical features, microarray-derived data from 22 GISTs were interpreted using a principal component analysis (PCA). Three relevant principal component representing mutation of KIT, PDGFRA and chromosome 14q deletion were identified from the interpretation of the oligonucleotide microarray data with PCA. After supervised analysis, there was at least a two fold difference in expression between GISTs with KIT and PDGFRA mutation in 70 genes. Our findings demonstrate that mutations of KIT and PDGFRA affect differential activation and expression of some genes, and can be used for the molecular classification of GISTs.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract (Lewin et al., 1992; Fletcher et al., 2002) . The constituent tumor cells are similar morphologically and immunohistochemically to the interstitial cells of Cajal Kindblom et al., 1998) , thus suggesting that GISTs originate from stem cells that differentiate toward ICCs.
Recent molecular genetic studies have demonstrated that gain-of-function mutations of the v-kit HardyZuckerman 4 feline sarcoma viral oncogene homolog (KIT) proto-oncogene, a member of receptor tyrosine kinase III family (Besmer et al., 1986) , are the most frequent and important changes in the development of GISTs (Besmer et al., 1986; Hirota et al., 1998; Nakahara et al., 1998) . Mutations in KIT result in ligand-independent kinase activity and autophosphorylation of KIT (Kitayama et al., 1995; Ma et al., 1999) . The KIT mutation is known to be present in 41 to 92% of GISTs (Lasota et al., 1999; Taniguchi et al., 1999; Kim et al., 2000; Lux et al., 2000; Rubin et al., 2001; Choi et al., 2003) . Activating mutations of plateletderived growth factor receptor a (PDGFRA) have recently been found in a subset of GISTs lacking KIT mutations (Heinrich et al., 2003) . KIT and PDGFRA belong to the same subfamily of receptor tyrosine kinase III (Blume-Jensen and Hunter, 2001; Pawson, 2002) , and the activating mutations of these two genes are mutually exclusive in GISTs. The mutations of these two genes can thus be regarded as alternative oncogenic mechanisms in GISTs.
Although the mutually exclusive activating mutations of KIT and PDGFRA appear to contribute to the development of GIST through similar pathways, the specific downstream pathways, and their impact on the gene expression profile have not been evaluated. We therefore carried out a transcriptional gene expression study on 22 GISTs and compared the results with respect to the type of mutation status, KIT and PDGFRA.
Results
Clinicopathologic characteristics and mutation status of KIT and PDGFRA in GISTs Among the 22 GISTs, five cases were classified as benign (very low or low risk), 10 were classified as borderline (intermediate risk) and seven were classified as malignant (high risk). Immunoreactivity for KIT was present in 18. Immunoreactivity for CD34 and PDGFRA were found in 21 and 17 cases, respectively. 14q deletion was detected in 13 cases (Table 1) . KIT mutation was detected in 17 out of 22 cases. In the 17 GISTs with KIT mutation, 16 mutations were present in exon 11 and one mutation was present in exon 9. Deletion mutations were most frequent, and these were found in seven cases, while point mutations were found in six cases and insertions were found in four cases. Among the remaining five cases lacking KIT mutations, three cases had PDGFRA mutation, all of them were being point mutations in exon 18.
Unsupervised clustering analysis distinguish a subset of GISTs with lacking KIT mutation
The relative expression of each gene was evaluated by comparing the degree of the expression to the Universal Human Reference RNA. Previous reports (Allander et al., 2001; Nielsen et al., 2002) have described homogeneous gene expression profiles in GISTs in contrast to the profiles of other types of mesenchymal tumors. In this study, we initially attempted a molecular pattern analysis to determine whether our spottedoligoarray system was able to identify different subsets of GISTs by molecular profiling. All of the oligoarray data of the samples described in this study are presented on our web page (http://www.molpathol.org/data/ GIST-arraydata.txt). With a relevant set of 4693 prefiltered genes (see 'Materials and methods'), we conducted a complete-linkage hierarchical clustering analysis of 22 arrays. A two-way hierarchical clustering analysis did not completely distinguish GISTs with KIT mutation and those lacking KIT mutation. However, 13 out of 17 GISTs with KIT mutations formed a cluster separated by two small clusters. Moreover, among the five GISTs lacking KIT mutation, three GISTs with PDGFRA mutation and one GIST lacking both KIT and PDGFRA mutations formed a cluster (Supplementary Figure 1) Figure 1a) , and component 5 was significantly correlated with the KIT and PDGFRA mutation status (P ¼ 0.01, Mann-Whitney rank-sum test, Table 2, Figure 1b) .
We then tried to identify a robust set of mutation type-related genes by a supervised rank-sum analysis using the Mann-Whitney rank-sum test. To identify the genes that were differentially regulated in GISTs according to the mutation status of KIT or PDGFRA, we selected 20 GISTs (17 GISTs with KIT mutation and three GISTs with PDGFRA mutation; two GISTs Gene expression profile of the GISTs HJ Kang et al lacking both mutations were excluded), and we used a stringent selection criterion (see 'Materials and methods'). In all, 70 genes were found to be either upregulated (seven genes) or downregulated (63 genes) in 17 GISTs with KIT mutation compared to the three GISTs with PDGFRA mutation. The genes that were differentially expressed in GISTs with PDGFRA mutation are listed in Figure 2A and Supplementary Table 1 . In order to examine the reliability of the microarray data, we selected KIT and two upregulated genes (IGFBP2 and PDGFRA) in GISTs with PDGFRA mutation. The expressions of these genes were analysed by semiquantitative multiplex RT-PCR using the RNA samples used for the microarray analysis. The results of RT-PCR were consistent for all three genes (data not shown).
Mutation of KIT and PDGFRA are directly correlated to the overexpression of active KIT and PDGFRA
The effect of mutation on the activation of KIT and PDGFRA was examined at the RNA and protein levels ( Figure 2A and B). The levels of KIT and PDGFRA protein and their phosphorylation status were analysed by Western blotting. KIT expression was increased in GISTs with KIT mutation ( Figure 2B ). The average relative expression ratio of KIT was 5.6 in 17 cases with KIT mutation and 0.1 in five GISTs lacking KIT mutation. In contrast, PDGFRA expression was found in GISTs regardless of PDGFRA mutation status: 14 out of 17 GISTs with KIT mutation expressed PDGFRA in addition to all three GISTs with PDGFRA mutation. To determine whether KIT and PDGFRA expressions were related to their active forms, we examined their phosphorylation status. Out of 17 GISTs expressing KIT, 14 GISTs expressed phospho-KIT, whereas phospho-PDGFRA was detected in only four out of 17 GISTs expressing PDGFRA ( Figure 2B ). These results indicate that activation of KIT and PDGFRA was related to the mutation status of KIT and PDGFRA, respectively, because 13 of 17 GISTs with KIT mutation expressed activated KIT and all three GISTs with PDGFRA mutation expressed activated PDGFRA.
Immunohistochemically, KIT and PDGFRA were detected mainly in the cytoplasm of the tumor cells. KIT expression was detected in 17 GISTs with KIT mutation and one of five GISTs lacking KIT mutation. The cytoplasmic PDGFRA expression was detected in all three GISTs with PDGFRA mutation, 13 of 17 GISTs with KIT mutation and one of two GISTs lacking both KIT and PDGFRA mutations (Table 1 and Figure 2c ).
Expression of activated STAT3, AKT and Erk1/2 in GISTs with KIT and PDGFRA mutation
Since we found that the mutation status of KIT and PDGFRA was directly related to the expression of activated KIT and PDGFRA, we evaluated the expression of the signaling molecules that are known to play key roles downstream of receptor tyrosine kinase III. We selected three GISTs with PDGFRA mutation (cases 1, 3 and 18) and five GISTs with KIT mutation (cases 5, 12, 15, 19 and 22), and we analysed STAT3 for the evaluation of JAK/STAT pathway, Erk1/2 of the MAPK pathway and AKT of the PI3 K pathway. As expected, all of the above molecules were expressed in their active forms in all of our GISTs; however, the level of their expression differed according to mutation status of KIT and PDGFRA. The expressions of phospho-STAT3 and phospho-AKT were more intense in GISTs with KIT mutation than in those with PDGFRA mutation, while expression of phospho-Erk1/2 was stronger in GISTs with PDGFRA mutation. There was no difference in the protein expression level of STAT3, AKT and Erk1/2 between our GISTs with KIT and PDGFRA mutation (Figure 3) . 
Discussion
In this study, we have analysed the mutations of KIT and PDGFRA in our 22 GISTs, and compared the gene expression profiles according to the mutation status of these two genes. We found some differences in the gene expression profiles of GISTs according to the KIT and PDGFRA mutations. These findings suggest that GISTs may be classified at the molecular level according to the mutation status of KIT and PDGFRA.
Mutation of KIT has been implicated as a major genetic event in the tumorigenesis of GISTs, because most GISTs have shown gain-of-function mutation of KIT and germline mutation of KIT has been found in familial GISTs (Lasota et al., 1999; Taniguchi et al., 1999; Hirota et al., 2000; Lux et al., 2000; Maeyama et al., 2001) . Recently, the mutation of PDGFRA has been considered as another causative genetic event (Heinrich et al., 2003; Hirota et al., 2003) , as PDGFRA mutations were found in most of the GISTs lacking KIT Red circles indicate GISTs with the loss of chromosome 14q, and blue circles indicate the GISTs without the loss of chromosome 14q. This plot demonstrates that subcategories of GISTs are present according to 14q deletion and PDGFRA mutation status. Three GISTs with PDGFRA mutation form a separate cluster on the plot (marked by an ellipse) mutation, and both PDGFRA and KIT belong to the same subfamily of receptor tyrosine kinase III (BlumeJensen and Hunter, 2001; Pawson, 2002) . Thus, it has been speculated that the mutations of these two genes facilitate the transformation and progression of GISTs through the same pathway. We confirmed here that the mutations of KIT and PDGFRA are mutually exclusive in our GISTs. Furthermore, our data demonstrated that the mutations of KIT and PDGFRA correlated with their activation. The overexpression of KIT was found in 16 out of 17 GISTs with KIT mutation and one out of five GISTs lacking KIT mutation by Western blotting analysis. We have also demonstrated the presence of phosphorylated KIT in most GISTs with KIT mutation, and thus provided direct evidence for the role of KIT mutation in tumorigenesis. In contrast, the overexpression of PDGFRA was detected in most of GISTs regardless of PDGFRA mutation. PDGFRA was detected in 14 out of 17 GISTs with KIT mutation, in all three GISTs with PDGFRA mutation and in one out of two GISTs lacking both KIT and PDGFRA mutations. These findings are similar to a previous report where a subset of GISTs with KIT mutation expressed PDGFRA . In this study, we found Figure 2 Expression of KIT and PDGFRA at the RNA (A) and protein levels (B and C). (A) Supervised hierarchical cluster analysis of gene expression patterns, and the mutation status of KIT and PDGFRA of 20 GISTs. To detect differentially expressed genes in a given subclass, we ranked the genes using the Mann-Whitney rank-sum test. Outlier genes responsible for mutation status were selected by Po0.01. In addition, significant outlier subset genes were further narrowed by filtering genes showing greater than 72-fold expression changes in GISTs with KIT mutation compared to the average values from GISTs with PDGFRA mutation. Cases 1, 3 and 18 showed PDGFRA mutation (marked as blue), and the other 17 cases showed KIT mutation (marked red). (B) RNA expressions of KIT and PDGFRA were correlated to the mutation status of KIT and PDGFRA (M, mutated type; W, wild type). In contrast, homogeneous CD34 expression was noted regardless of KIT or PDGFRA mutation. In all, 17 GISTs with KIT mutation showed an overexpression of KIT and activated KIT protein, while only one (case 3) of three GISTs (cases 1, 3 and 8) with PDGFRA mutation expressed KIT and showed activated KIT protein. PDGFRA was expressed in 14 of 17 GISTs with KIT mutation and all three GISTs with PDGFRA mutation; however, only one (case 5) out of 17 GISTs with KIT mutation and all three GISTs (cases 1, 3 and 18) with PDGFRA mutation demonstrated activated PDGFRA. (C) Example of histological (a and e), immunohistochemical analysis of KIT (b and f), PDGFRA (c and g) and CD34 (d and f). Overexpression of KIT and PDGFRA was directly correlated to the mutation status of KIT and PDGFRA, respectively that the level of PDGFRA expression was higher in GISTs with PDGFRA mutation, in which activated PDGFRA was detected in only four out of 18 cases, and three of these exhibited the PDGFRA mutation. These findings indicate that the mutation of PDGFRA directly correlates with the activation of PDGFRA, and may be involved in the tumorigenesis of GISTs.
KIT and PDGFRA are members of the receptor tyrosine kinase III family that are known to transduce their signals through the JAK/STAT pathway (Ihle and Kerr 1995; Schindler and Darnell, 1995; Weiler et al., 1996; Brizzi et al., 1999; Mui, 1999) , Ras/ERK pathway (Porri and McCormick, 1996; Burack and Sturgill, 1997) , PLC-g pathway (Zhang et al., 1996; Barker et al., 1998) , PI3K pathway (Timokhina et al., 1998) and PDK and AKT (Schlessinger, 2000) pathways. All of these pathways have been suggested to contribute to tumor development, as they have been shown to regulate the cell cycle and cell differentiation through the activation of transcription factors . Our oligonucleotide microarray analysis allowed us to evaluate 15 genes (AKT, GRB, JAK, MAP2 K, MAPK, PDK, PI3 K, PIP3, RAF, RAS, SHC, SRC, STAT1, STAT3, STAT5) that are known to be involved in these signal transduction pathways. There were no remarkable differences in their RNA expression levels in our GISTs with KIT mutation and PDGFRA mutation. However, we did not find differences in the expression levels of activated proteins related to the JAK/STAT, PI3 K and MAPK signaling pathways between the GISTs with KIT mutation and those with PDGFRA mutation. The expressions of phospho-STAT3 and phospho-AKT were more intense in the GISTs with KIT mutation than in those with PDGFRA mutation, while expression of phospho-Erk1/2 was stronger in GISTs with PDGFRA mutation. These findings suggest that there are some quantitative differences in the activation of the proteins downstream of receptor tyrosine kinase III between GISTs with KIT mutation and those with PDGFRA mutation, and that these differences may be associated with differential gene expression.
GISTs show unique chromosomal, morphological and immunohistochemical characteristics. Recently, there have been two studies on the gene expression of GIST, and both have demonstrated that the gene expression profile of GISTs is different from those of the other types of mesenchymal tumors (Allander et al., 2001; Nielsen et al., 2002) . Although these data indicated that GISTs are unique and homogeneous tumors, they show some diverse intertumoral variations at the clinical, morphological and genetic level. Clinically, GISTs are classified as benign, borderline or malignant tumors. Histopathologically, they exhibit two distinct forms, spindle and epithelioid, and mixed patterns are detected in some cases. In addition, several peculiar histologic patterns, such as alveolar pattern, have been detected in some GISTs. The genetic characteristics of GISTs are also diverse. The loss of the long arm of chromosome 14 was detected in 69 to 80% of GISTs (El-Rifai et al., 1998 , 2000 Kim et al., 2000) , and KIT mutation was found in 41 to 92% of GISTs (Lasota et al., 1999; Taniguchi et al., 1999; Kim et al., 2000; Lux et al., 2000; Rubin et al., 2001; Choi et al., 2003) . In this study, we attempted to classify GIST at the molecular level according to the overall gene expression profiles. Our data suggest that GISTs may be categorized into subsets according to the mutation status of KIT and PDGFRA. The direct link between molecular classification and the activating mutations should be regarded as an important finding. Different gene expression patterns of the GISTs according to the anatomic tumor site and the different gene mutation status have recently been reported (Antonescu et al., 2004; Subramanian et al., 2004) . When we correlated the molecular classification with the clinical, pathological and genetic characteristics by the PCA model, 14q deletion, KIT mutation and PDGFRA mutation had strong impacts. Furthermore, our data reveal that 70 genes are expressed differentially between the GISTs with the KIT and GISTs with the PDGFRA mutation. Most of these genes are overexpressed in GISTs with PDGFRA mutation. Some of these genes have known functions in signal transduction (ASB2, IGFBP2, IGFBP4, PDGFRA, RPS6KA1 and S100A1) and development (RELN and ANGPTL2). Further analysis in a larger series of cases and determination of the possible functional mechanism of these differentially expressed genes should clarify the molecular characteristics of KIT and PDGFRA mutation.
Materials and methods

Patients and tissue samples
In all, 22 GISTs of the stomach were included in this study. All cases were identified prospectively and consecutively in the Department of Pathology at Yonsei University Medical Center from September 1995 to November 2002 for molecular marker studies. Authorization for the use of those tissues for research Figure 3 Expression level of activated STAT3, AKT and Erk1/2. Expressions of phospho-STAT3 and phospho-AKT were more intense in GISTs with KIT mutation than in those with PDGFRA mutation, while expression of phospho-Erk1/2 was stronger in GISTs with PDGFRA mutation. No difference in the protein expression level of STAT3, AKT and Erk1/2 was noted between five GISTs with KIT mutation and three GISTs with PDGFRA mutation was obtained from the Institutional Review Board. Among these 22 GISTs, 12 had previously reported for chromosomal and proteome analysis (Kim et al., 2000; Choi et al., 2003) . Information on demographic features and tumor sites was obtained from hospital chart and clinicians. The subjects of study included 13 females and nine males ranging in age from 36 to 78 years (Table 1) . Conventional pathologic parameters (tumor size, number and grade) were examined prospectively without prior knowledge of the molecular data. The tumor grade of GISTs was divided into three groups according to the criteria of Lewin (Lewin et al., 1992; Fletcher et al., 2002) .
For DNA and RNA extraction, fresh tumors were obtained immediately after surgical excision, and stored at À701C before use. To enrich the tumor cell population, areas containing more than 90% of tumor cells were sampled from hematoxylin-eosin-stained slides using the cryostat microdissection technique. Genomic DNA was prepared using the sodium dodecyl sulfate-proteinase K and phenol-chloroform extraction method.
Mutation analysis of KIT and PDGFRA
Somatic mutations in exons 9, 11, 13 and 17 of KIT and mutations in exons 12 and 18 of PDGFRA were analysed in our 22 GISTs using PCR-based assay as described previously (Lasota et al., 1999; Taniguchi et al., 1999; Lux et al., 2000; Rubin et al., 2001; Heinrich et al., 2003) . PCR products were separated on 6% polyacrylamide gels, followed by autoradiography for single-strand conformational polymorphism analysis. The PCR products were also sequenced using an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Microarray formulation
High-density spotted oligonucleotide microarrays were manufactured at the array core facility at Genome Institute of Singapore. The human Oligolibraryt was purchased from Compugen/Sigma-Genosys. It consisted of 18 861 oligonucleotides, representing 18 664 LEADSt clusters and 197 controls (GAPDH). Sixtymers of synthesized oligomers were robotically printed and processed.
RNA preparation and hybridization
Total RNA was extracted from microdissected frozen tissues using an RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Total RNA (20 mg) was used as input for cDNA target synthesis as described previously (Joseph et al., 1997) . The targets and Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) were hybridized to an oligonucleotide microarray containing 18 664 probe sets representing 18 664 unique (LEADSt) genes, and the array was scanned using GenePix scanners. Expression values for each gene were calculated by using the GenPix Pro 4.0 analysis software.
Aggolomerative hierarchical clustering
Unsupervised hierarchical clustering analysis was used to classify the 22 GISTs according to the gene expression. We used a data set of genes that satisfied the filtering criteria: genes having more than 70% of log-transformed ratio values (presenting in across all arrays) were taken and genes with less than 0.35 standard deviations of log-transformed ratio were discarded. The selected gene data set was then applied to complete-linkage hierarchical clustering analysis using the uncentered correlation similarity metric method in Cluster version 2.20. The results of expression map were visualized with Treeview version 1.60 software (http://rana.lbl.gov/ EisenSoftware.htm).
Principal component analysis
PCA is one of the unsupervised approach techniques. In contrast to hierarchical clustering, PCA permits sample classification into multiple independent components. PCA searches for key components in a multidimensional data set to explain differences among the observations (Raychaudhuri et al., 2000) . Initially, the set of genes that had 100% of logtransformed ratio values presented in all arrays) were selected. The data of the selected genes were applied to PCA by using Cluster version 2.20. The data of 22 components and eigenvalues for each component were obtained. We compared each component with clinicopathological data, the status of KIT and PDGFRA mutation and deletion of long arm of chromosome 14.
Identification of differentially expressed genes according to the mutation status of KIT and PDGFRA To determine whether GISTs can be classified according to the mutation status of KIT or PDGFRA, 20 cases (17 with KIT mutation and three with PDGFRA mutation) of GISTs were assessed using the two-way hierarchical clustering analysis. To detect differentially expressed genes according to the mutation status of KIT or PDGFRA, we ranked the genes using the Mann-Whitney rank-sum test. Outlier genes responsible for GISTs with KIT or PDGFRA mutation were selected by Po0.01. In addition, significant outlier subset genes were further narrowed down by filtering genes showing greater than 72-fold expression changes in GISTs with KIT mutation compared to the average values from GISTs with PDGFRA mutation (Table 2) .
Western blot analysis
Whole lysates from tumor specimens were prepared by using lysis buffer (50 mM Tris (pH 7.4), 1% Triton X-100, 5 mM EDTA, 1 mM KCl, 140 mM NaCl, 2 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1% aprotinin, 1 mM leupeptin and 1 mM sodium ortho-vanadate). Total protein lysates (20 mg) were loaded into each lane, sizefractionated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane that was blocked with Tris-buffered saline-Tween 20 containing 5% skim milk. Primary antibodies, KIT (Santacruz Biotech, Santa Cruz, CA, USA), PDGFRA (Santacruz Biotech), glyceraldehyde-3-phosphate dehydrogenase (G3PDH; Trevigen, Gaitherburg, MD, USA), Erk1/2 and phospho-Erk1/2 (Santacruz Biotech), STAT3 and phospho-STAT3 (Cell signaling, Beverly, MA, USA), AKT and phospho-AKT (Cell signaling) and phosphotyrosine-HRP (Amersham Pharmacia Biotech, UK) were incubated for 1 h at room temperature. After washing, membranes were incubated with HRP-conjugated secondary antibody (Santacruz Biotech), washed and then developed with ECL-Plus (Amersham Pharmacia Biotech).
Immunoprecipitation
Tissue lysates (500 mg) were precleared and gently rocked on an orbital shaker with immunoprecipitating antibodies, KIT (Santacruz Biotech) and PDGFRA (Santacruz Biotech) at 41C. The immune complexes were collected by centrifugation and boiled to dissociate the immunocomplexes from the beads. The beads were collected by centrifugation and protein separation was performed by SDS-PAGE with the supernatant fraction.
Semiquantitative RT-PCR
First-strand cDNA was synthesized from 1 mg of total RNA using random hexamer primers (Qiagen) and M-MLV Reverse Transcriptase (Invitrogen, San Diego, CA, USA) according to the manufacturer's instructions. cDNA (20 ng) from each sample was used in each reaction. All the RT-PCR primer sets were designed to contain an exon-exon junction, and they were as follows: KIT, 5 0 -AGTGAGGCCAGCCTTCAAA-3 0 and 5 0 -GGTTTGGGGAATGCTTCATA-3 0 ; PDGFRA, 5 0 -TTC AGGAAATAAGGTATCGAAGC-3 0 and 5 0 -GATGGTCTC CTCCACTTTGG-3 0 ; IGFBP2, 5 0 -GCAGACAATGGCGAT-GACC-3 0 and 5 0 -GTTGGGGTTCACACACCAG-3 0 ; and bActin, 5 0 -ACAGAGTACTTGCGCTCAGGAG-3 0 and 5 0 -TG TATGCCTCTGGTCGTACCAC-3 0 . b-Actin was used as a quantitative internal control. After RT-PCR, 5 ml aliquots of the products were subjected to 2% agarose gel electrophoresis and subsequently stained with ethidium bromide.
Immunohistochemical analysis
The tissue array was constructed from formalin-fixed and paraffin-embedded tissues (Petagen Inc., Seoul, Korea) and used for the immunostaining. Deparaffinization and rehydration were performed using xylene and alcohol. The sections were treated with 0.3% hydrogen peroxidase for 3 min and blocking antibody for 30 min. The antibodies used were as follows: KIT (polyclonal, DAKO; 1 : 1000 (v/v)), PDGFRA (polyclonal, Santacruz Biotech; 1 : 200 (v/v) ) and CD34 (monoclonal, DAKO; 1 : 50 (v/v)). The avidin-biotin complex methodology was employed. The chromogen was diaminobenzidine and counterstaining was carried out with methyl green. The staining of KIT, PDGFRA and CD34 were categorized as either expressed and absent: cases with definite staining in more than 10% of the tumor cells were categorized as expressed, and cases with staining in less than 10% of the tumor cells were categorized as absent.
